Literature DB >> 18340566

Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats.

N N Patel1, C M Crincoli, E L Kennedy, D M Frederick, R Tchao, P J Harvison.   

Abstract

1. The thiazolidinedione ring present in drugs available for type II diabetes can contribute to hepatic injury. Another thiazolidinedione ring-containing compound, 3-(3,5-dichlorophenyl)-2,4-thiazoli-dinedione (DCPT), produces liver damage in rats. Accordingly, the effects of gender, dose, and time on DCPT hepatotoxicity were therefore evaluated. 2. Male rats were more sensitive to DCPT (0.4-1.0 mmol kg(-1) by intraperitoneal administration) as shown by increased serum alanine aminotransferase levels and altered hepatic morphology 24 h post-dosing. Effects in both genders were dose dependent. In males, DCPT (0.6 mmol kg(-1)) produced elevations in alanine aminotransferases and changes in liver sections 3 h after dosing that progressively worsened up to 12 h. DCPT-induced renal effects were mild. 3. It is concluded that male rats are more susceptible to DCPT hepatotoxicity and that damage occurs rapidly. DCPT primarily affects the liver and can be a useful compound to investigate the role of the thiazolidinedione ring in hepatic injury. However, the gender dependency and rapid onset of DCPT hepatotoxicity require further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18340566      PMCID: PMC2922973          DOI: 10.1080/00498250701830267

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  42 in total

Review 1.  Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.

Authors:  J Kohlroser; J Mathai; J Reichheld; B F Banner; H L Bonkovsky
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

Review 2.  Troglitazone and liver injury: in search of answers.

Authors:  Mario Chojkier
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

3.  In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones.

Authors:  Dietmar Rakowitz; Rosanna Maccari; Rosaria Ottanà; Maria Gabriella Vigorita
Journal:  Bioorg Med Chem       Date:  2005-10-03       Impact factor: 3.641

4.  Hepatic failure in a patient taking rosiglitazone.

Authors:  L M Forman; D A Simmons; R H Diamond
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

5.  Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.

Authors:  Rubén Alvarez-Sanchez; François Montavon; Thomas Hartung; Axel Pähler
Journal:  Chem Res Toxicol       Date:  2006-08       Impact factor: 3.739

6.  Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes.

Authors:  T M Baughman; R A Graham; K Wells-Knecht; I S Silver; L O Tyler; M Wells-Knecht; Z Zhao
Journal:  Drug Metab Dispos       Date:  2005-03-11       Impact factor: 3.922

Review 7.  Mechanistic classification of liver injury.

Authors:  John M Cullen
Journal:  Toxicol Pathol       Date:  2005       Impact factor: 1.902

8.  Dose- and time-dependent effects of 2,3,7,8-tetrabromodibenzo-p-dioxin on rat liver.

Authors:  Hisao Ohbayashi; Toshiaki Sasaki; Michiharu Matsumoto; Tadashi Noguchi; Kazunori Yamazaki; Shigetoshi Aiso; Kasuke Nagano; Heihachiro Arito; Seigo Yamamoto
Journal:  J Toxicol Sci       Date:  2007-02       Impact factor: 2.196

9.  Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.

Authors:  Michie M K Ong; Calivarathan Latchoumycandane; Urs A Boelsterli
Journal:  Toxicol Sci       Date:  2006-12-05       Impact factor: 4.849

Review 10.  Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.

Authors:  Yasuhiro Masubuchi
Journal:  Drug Metab Pharmacokinet       Date:  2006-10       Impact factor: 3.614

View more
  5 in total

1.  Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.

Authors:  Douglas M Frederick; Erina Y Jacinto; Niti N Patel; Thomas H Rushmore; Ruy Tchao; Peter J Harvison
Journal:  Toxicol In Vitro       Date:  2011-09-22       Impact factor: 3.500

2.  A long-term study on female mice fed on a genetically modified soybean: effects on liver ageing.

Authors:  Manuela Malatesta; Federica Boraldi; Giulia Annovi; Beatrice Baldelli; Serafina Battistelli; Marco Biggiogera; Daniela Quaglino
Journal:  Histochem Cell Biol       Date:  2008-07-22       Impact factor: 4.304

3.  Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.

Authors:  Niti N Patel; Christine M Crincoli; Douglas M Frederick; Ruy Tchao; Peter J Harvison
Journal:  J Appl Toxicol       Date:  2011-02-21       Impact factor: 3.446

4.  Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells.

Authors:  Alyssa M Keil; Douglas M Frederick; Erina Y Jacinto; Erica L Kennedy; Randy J Zauhar; Nathan M West; Ruy Tchao; Peter J Harvison
Journal:  Toxicol In Vitro       Date:  2015-07-17       Impact factor: 3.500

5.  Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.

Authors:  Christine M Crincoli; Niti N Patel; Ruy Tchao; Peter J Harvison
Journal:  Toxicology       Date:  2008-06-25       Impact factor: 4.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.